Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells
- PMID: 8906588
Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells
Abstract
The human apoSAA proteins comprise both acute phase (apoSAA1, apoSAA2) and constitutive (apoSAA4) isoforms; all are expressed in human atherosclerotic lesions as well as in liver. Recombinant acute phase apoSAA binds cholesterol with an affinity of approximately 170 nM and enhances cholesterol uptake by HepG2 cells (J. Lipid Res. 1995. 36:37-46). In the present study, we sought to define the region of acute phase apoSAA involved in cholesterol binding and to investigate the ability of constitutive apoSAA4 to bind cholesterol. Binding of [3H]cholesterol to apoSAAp was inhibited by unlabeled cholesterol (1-100 nM), but not significantly by vitamin D and estradiol. Direct binding of acute phase, but not constitutive, apoSAA to the surfaces of polystyrene microtiter wells was strongly diminished in the presence of cholesterol. The ability of apoSAAp to bind cholesterol was inhibited by antibodies to human apoSAA1 and to peptide 1-18 of apoSAA1. There was only slight inhibition of cholesterol binding by antibodies to peptide 40-63, and no inhibition by antibodies to peptides spanning regions containing amino acid residues 14-44 and 59-104. [3H]cholesterol uptake by neonatal rabbit aortic smooth muscle and HepG2 cells was enhanced by a synthetic peptide corresponding to amino acids 1-18 of hSAA1, but not by peptides corresponding to amino acids 1-18 of hSAA4. [3H]cholesterol uptake by HepG2 cells was slightly increased by a peptide corresponding to amino acids 40-63 of hSAA1. These findings suggest that apoSAA modulates the local flux of cholesterol between cells and lipoproteins during inflammation and atherosclerosis.
Similar articles
-
Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux.J Lipid Res. 1995 Jan;36(1):37-46. J Lipid Res. 1995. PMID: 7706946
-
The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis.J Biol Chem. 1999 Mar 12;274(11):7172-81. doi: 10.1074/jbc.274.11.7172. J Biol Chem. 1999. PMID: 10066777
-
Regulation of extrahepatic apolipoprotein serum amyloid A (ApoSAA) gene expression by interleukin-1 alpha alone: synthesis and secretion of ApoSAA by cultured aortic smooth muscle cells.Scand J Immunol. 1997 Sep;46(3):284-91. doi: 10.1046/j.1365-3083.1997.d01-128.x. Scand J Immunol. 1997. PMID: 9315118
-
SAA, an apoprotein of HDL: its structure and function.Ann N Y Acad Sci. 1982;389:183-9. doi: 10.1111/j.1749-6632.1982.tb22136.x. Ann N Y Acad Sci. 1982. PMID: 7046575 Review.
-
Serum Amyloid A (SAA) Proteins.Subcell Biochem. 2020;94:421-436. doi: 10.1007/978-3-030-41769-7_17. Subcell Biochem. 2020. PMID: 32189310 Review.
Cited by
-
Biological Characterization of Commercial Recombinantly Expressed Immunomodulating Proteins Contaminated with Bacterial Products in the Year 2020: The SAA3 Case.Mediators Inflamm. 2020 Jul 6;2020:6087109. doi: 10.1155/2020/6087109. eCollection 2020. Mediators Inflamm. 2020. PMID: 32694927 Free PMC article.
-
Serum amyloid A sequesters diverse phospholipids and their hydrolytic products, hampering fibril formation and proteolysis in a lipid-dependent manner.Chem Commun (Camb). 2018 Apr 3;54(28):3532-3535. doi: 10.1039/C8CC01424H. Chem Commun (Camb). 2018. PMID: 29565436 Free PMC article.
-
Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis.Biochem J. 1999 Nov 15;344 Pt 1(Pt 1):7-13. Biochem J. 1999. PMID: 10548527 Free PMC article.
-
Urea-induced denaturation of apolipoprotein serum amyloid A reveals marginal stability of hexamer.Protein Sci. 2005 Jul;14(7):1811-7. doi: 10.1110/ps.051387005. Epub 2005 Jun 3. Protein Sci. 2005. PMID: 15937280 Free PMC article.
-
SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma.Oncogene. 2015 Feb 12;34(7):878-89. doi: 10.1038/onc.2014.12. Epub 2014 Mar 10. Oncogene. 2015. PMID: 24608426
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical